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Background: 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) misuse is associated with
hyponatremia particularly in women. Hyponatremia is possibly due to inappropriate secretion of
plasma arginine vasopressin (AVP).
Objective: To assess whether MDMA increases plasma AVP and copeptin in healthy male and
female subjects and whether effects depend on MDMA-induced release of serotonin and norepi-
nephrine. Copeptin, theC-terminal part of theAVPprecursorpreprovasopressin, is cosecretedwith
AVP and can be determined more reliably.
Methods:We used a randomized placebo-controlled crossover design. Plasma and urine osmola-
lities as well as AVP and copeptin levels were measured in 16 healthy subjects (eight female, eight
male) at baseline and afterMDMA (125mg) administration. In addition,we testedwhether effects
ofMDMAonAVPandcopeptin secretioncanbepreventedbypretreatmentwith the serotoninand
norepinephrine transporter inhibitor duloxetine (120 mg), which blocks MDMA-induced trans-
porter-mediated release of serotonin and norepinephrine.
Results:MDMA significantly elevated plasma copeptin levels at 60 min and at 120 min compared
with placebo inwomenbut not inmen. The copeptin response toMDMA inwomenwas prevented
by duloxetine. MDMA also nonsignificantly increased plasma AVP levels in women, and the effect
was prevented by duloxetine. Although subjects drank more water after MDMA compared with
placebo administration, MDMA tended to increase urine sodium levels and urine osmolality com-
pared with placebo, indicating increased renal water retention.
Conclusion:MDMA increased plasma copeptin, a marker for AVP secretion, in women but not
in men. This sex difference in MDMA-induced AVP secretion may explain why hyponatremia is
typically reported in female ecstasy users. The copeptin response to MDMA is likely mediated
via MDMA-induced release of serotonin and/or norepinephrine because it was prevented by
duloxetine, which blocks the interaction of MDMA with the serotonergic and noradrenergic
system. (J Clin Endocrinol Metab 96: 2844–2850, 2011)
Abuseof3,4-methylenedioxymethamphetamine (MDMA,ecstasy) has been associated with the syndrome of
inappropriate secretion of antidiuretic hormone (SIADH)
(1, 2) and symptomatic hyponatremia particularly in
women (3, 4). Specifically, a case series of ecstasy-associ-
ated hyponatremia included 18 cases, of which 17 were
women (4). Another larger retrospective series of ecstasy
exposures reported to a poison center found hyponatre-
mia (Na130mmol/liter) in 73 (38.8%) of 188 cases (3).
Of the 73 cases with hyponatremia, 55 (75.3%) were
women and 18 (24.7%) men (3). Thus, female sex was
significantly associated with increased odds of hypona-
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tremiaand increasedoddsof associated comaamong these
cases (3). A small nonblinded laboratory study showed
that MDMA significantly increased plasma concentra-
tions of arginine vasopressin (AVP) at 1–4 h after con-
trolled MDMA administration in eight healthy male
volunteers (5, 6). This study provides evidence for a stim-
ulatory effect of MDMA on AVP secretion. However, no
female subjects were included. We assessed MDMA ef-
fects on AVP system activation and associated changes in
plasma and urine osmolality as well as sodium levels in
resting healthy subjects with ad libitum water intake in a
controlled laboratory setting.
MDMA is a substrate of both the serotonin and nor-
epinephrine transporter (7). It enters presynaptic nerve
terminals andpotently releases serotonin andnorepineph-
rine through the transporter (7). AVP secretion is thought
to be regulated by serotonergic (8) and noradrenergic (9)
pathways, and these monoamines could act as mediators
for the effects ofMDMAon theAVPsystem.TheMDMA-
induced carrier-mediated release of serotonin and norepi-
nephrine can be reduced by serotonin and norepinephrine
transporter inhibitors, respectively (10, 11). We therefore
assessed whether blockade of both the serotonin and nor-
epinephrine transporter with duloxetine would prevent
potential effects of MDMA on AVP secretion in the pres-
ent study.
The reliable determination of plasma AVP is problem-
atic. We therefore measured copeptin in addition to AVP
levels. Copeptin is the C-terminal part of the AVP precur-
sor preprovasopressin. Copeptin is produced together
with AVP in equimolar ratio and exhibits similar kinetics
in response to osmotic changes (12–14). In contrast to
AVP, copeptin levels remain stable in serum or plasma
samples and can easily and reliably be measured (12).
Wehypothesized thatMDMAwould increaseAVPand
copeptin levels, particularly in women, and that pretreat-
ment with the serotonin-norepinephrine transport inhib-
itor duloxetine would prevent this effect.
Subjects and Methods
Study subjects
The study was performed in 16 healthy subjects (eight
women, eightmen).Womenwere (mean SD) 29.0 7.1 yr old.
Body weight was 59.0  6.9 kg. Men were 23.3  3.1 yr old.
Body weight was 79.5 9.8 kg. Exclusion criteria included age
under 18 or over 45 yr, pregnancy (urine pregnancy test before
each test session), bodymass index below18.5 or over 25 kg/m2,
personal or family (first-degree relatives) history of psychiatric
disorder, regular use of medications, chronic or acute physical
illness (normal physical exam, normal electrocardiogram, and
standard hematological and chemical blood analyses), smoking,
lifetime prevalence of illicit drug use over five times (except for
tetrahydrocannabinol), illicit drug use within the last 2 months,
and illicit drug use during the study (urine tests before test ses-
sions). Subjects were asked to abstain from excessive alcohol
consumptionbetween test sessions and inparticular to limit their
use to one glass on the day before the test sessions. Subjects
abstained from caffeinated beverages on the test days. Female
subjects were investigated during the follicular phase (d 2–14) of
their menstrual cycle when the reactivity to amphetamines (15)
andosmotic sensitivity (16) are expected to be similar tomen.All
subjects gave theirwritten informed consent before participating
in the study, and subjects were paid for participation.
Study procedures
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the Ethics Committee of Basel,
Switzerland. The use of MDMA in healthy subjects was autho-
rized by the Swiss Federal Office of Public Health, Bern, Swit-
zerland. The study was registered at www.clinicaltrials.gov
(number NCT00990067) with neuroendocrine measures as a
secondary outcome. We used a randomized placebo-controlled
crossover design with four conditions (placebo-MDMA, place-
bo-duloxetine, duloxetine-MDMA, and placebo-placebo) in
balanced order.Washout periods between sessions lasted 10–14
d. Duloxetine (120 mg) or placebo was administered twice 16
and 4 h before MDMA (125 mg) or placebo, respectively. We
assessed plasma and urine osmolality aswell as plasma and urine
sodium 4 h before and 120 min after MDMA/placebo adminis-
tration. Plasma levels of copeptinwere assessed 4 h before and at
60 and 120 min after MDMA/placebo. Plasma levels of AVP
were assessed 4 h before and 120 min after MDMA/placebo.
Subjects were not engaged in any physical activity andwere rest-
ing in hospital beds during the test session. Subjects had a small
standardizedbreakfast at thebeginningof each test session. Fluid
consumption was not restricted up to a total intake of 2000 ml
water during the session andwas recorded from4hbefore to120
min after MDMA/placebo administration when the last hor-
mone measurement was performed. In addition, saline was ad-
ministered via an iv catheter to keep catheters open for blood
sampling at a rate of 100 ml/h from 0–120 min after MDMA/
placebo administration. The study design also included addi-
tional assessments of subjective and cardiovascular effects,
blood drawings for pharmacokinetics, and monitoring of ad-
verse events for 6 h afterMDMA/placebo administration as will
bedescribedelsewhere (Simmler,L.D.,C.M.Hysek, J.Huwyler,
M. E. Liechti, unpublished data).
Measurements
Measurementswere done in duplicates in a blinded fashion in
a single batch. AVP was assessed in EDTA plasma using a RIA
(Direct Vasopressin RIA; Bu¨hlmann Laboratories AG, Scho¨nen-
buch/Basel, Switzerland). The lower detection limit was 0.82
pmol/liter, and the intraassay precisionwas 6.0%.Copeptin lev-
els were assessed using an immunoassay (LIA CT-proAVP;
B.R.A.H.M.S./ThermoFisher Scientific, Hennigsdorf/Berlin, Ger-
many) as described previously (12) and modified as described
previously (14).The lowerdetection limitwas0.4pmol/liter, and
the intraassay coefficient of variation was less than 5%. Sodium
concentrations were measured by indirect potentiometry (Hita-
chi 917; RocheDiagnostics, Rotkreuz, Switzerland).Osmolality
was measured by cryoscopy (Micro Osmometer; Advances In-
struments for Switzerland Instruments, Zurich, Switzerland).
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Study drugs
()MDMA hydrochloride (Lipomed AG, Arlesheim, Swit-
zerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 and 25 mg). Iden-
tical placebo (lactose) capsules were prepared. MDMA was ad-
ministered in a single absolute dose of 125 mg. This dose of
MDMA corresponds to a typical recreational dose of ecstasy,
and comparable doses of MDMA have previously been used in
controlled settings. Because MDMA was dosed in an absolute
dose of 125 mg, differences in body weight resulted in different
weight-adjusted relative MDMA doses of 1.6  0.23 mg/kg
(range, 1.4–2.1 mg/kg) in men and 2.1  0.25 mg/kg (range,
1.8–2.5 mg/kg) in women. Duloxetine (Cymbalta; Eli Lilly SA,
Vernier, Switzerland) was prepared as 60-mg gelatin capsules,
and identically looking placebo (lactose) capsules were similarly
prepared.
Statistical analysis
Repeated-measures ANOVAwith the factors drug (placebo-
placebo, duloxetine-placebo, placebo-MDMA, and duloxetine-
MDMA) and time (baseline, 60 min, and 120 min) stratified for
sex and followed by pairwise Tukey post hoc tests was used to
assess differences in the effects of the different drugs. Nonnor-
mally distributed variables were log nor-
malized before the ANOVA. Correlation
analyses were performed using Spearman’s
rankcorrelationsusing the total of all values
(n 128). All tests were two tailed, and the
significance level was set to P  0.05.
Results
ANOVA on plasma copeptin levels
yielded a significant drug  time  sex
interaction [F(6,84) 3.93; P 0.0017].
MDMAsignificantlyelevatedplasmaco-
peptin levels at60min (P0.001)andat
120 min (P 0.01) compared with pla-
cebo in women (Fig. 1A) but not in men
(Fig. 1B). The MDMA-induced increase
in plasma copeptin in women was pre-
vented by duloxetine pretreatment
bothat 60min (P0.001) and120min
(P  0.01) (Fig. 1A). A similar trend
was observed for AVP levels but drug
effects did not reach significance (Fig.
1, C and D). Oral liquid intake varied
across drug treatments, but there
were no sex differences [main effect of
drug: F(3,42)  8.62; P  0.001, no
drug  sex interaction]. Oral liquid
intake (mean SEM) was 612 50 ml
after placebo-placebo, 1267 118ml
after duloxetine-placebo (P  0.001
vs. placebo-placebo), 1198  130 ml
after placebo-MDMA (P  0.001 vs.
placebo-placebo), and 807  83 ml after duloxetine-
MDMA (P  0.02 vs. duloxetine-placebo, and P 
0.051 vs. placebo-MDMA). Urine osmolality decreased
significantly over time [main effect of time: F(1,14) 
62.69; P 0.001]. Urine osmolality tended to be higher
after placebo-MDMAor duloxetine-MDMA compared
with placebo-placebo or duloxetine-placebo as evi-
denced by a near-significant drug  time interaction in
the ANOVA [F(3,42)  2.70; P  0.058] (Fig. 2, A and
B). A similar trend was observed for urine sodium levels
[drug time interaction: F(3,42) 2.33;P 0.088] (Fig.
2, C and D). There were no significant drug effects on
plasma sodium levels or plasma osmolality (Fig. 2,
E–H). Circulating copeptin levels correlated with AVP
levels (all: rs 0.34, P 0.001; women: rs 0.53, P
0.001; men: rs  0.28, P  0.05]. Copeptin levels were
also correlated with plasma and urine osmolality [rs 
0.22; P  0.05 and rs  0.68; P  0.001, respectively]
as well as with plasma and urine sodium [rs  0.18; P 
A              B              
C              D
FIG. 1. Mean values  SEM for plasma levels of copeptin and AVP in eight female and eight
male healthy subjects 4 h before (PRE) and 60 and 120 min after MDMA (125 mg) or placebo.
A, MDMA significantly increased copeptin levels in women at 60 and 120 min after drug
administration compared with placebo. Duloxetine pretreatment prevented the MDMA-
induced elevation in circulating copeptin in women. B, MDMA did not alter copeptin levels in
men. C, Similar to its effects on MDMA-induced copeptin increases, duloxetine also prevented
the nonsignificant increase in AVP at 120 min after MDMA administration in women. D,
There were no drug effects on AVP levels in men. **, P  0.01; ***, P  0.001 vs. placebo-
placebo; ##, P  0.01; ###, P  0.001 vs. placebo-MDMA.
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0.05 and rs  0.28; P  0.01, respectively]. Baseline co-
peptin levels were significantly lower in women than men
[F(1,14)  8.38; P  0.012]. The relative dose of MDMA
(inmilligrams per kilogrambodyweight) did not correlate
with the MDMA-induced increase in plasma copeptin
within the two sex groups. In the present study, MDMA
also producedmarked subjective and cardiovascular stim-
ulant effects aswill be reported separately elsewhere (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data).
Discussion
We found that MDMA increased circulating copeptin, a
marker for AVP secretion, in women but not in men. This
sex difference inMDMA-induced AVP secretion is in line
with the clinical observation that ecstasy-associated hy-
ponatremia is typically reported in female users (3, 4).
Other sex differences in the response toMDMAor ecstasy
have previously been reported and include increased sub-
jective effects in women compared with men to equal
weight-adjusted doses of MDMA (18), more pronounced
depression after ecstasy use (19), and a potential increase
in serotonergic neurotoxicty in associationwith long-term
useof ecstasy inwomen (20).Thepresent findings indicate
that women may be at increased risk for developing hy-
ponatremia and associated neurotoxicity due to their sex-
specific stronger AVP response to MDMA. In addition,
the threshold levels of plasma sodium at which neurolog-
ical complications occur appear to be higher in women
than men (21, 22), and woman are more likely than men
to die from hyponatremic encephalopathy after surgery
(21, 23). Seizures and coma were also more frequently
reported in female cases of ecstasy-associated hypona-
tremia compared with men (3). However, ecstasy-asso-
ciated hyponatremia may have multiple causes, and
MDMA-induced AVP secretion may be only one of sev-
eral contributing factors. Dry mouth and physical ex-
ertion with sweating followed by hyperhydration with
electrolyte-free water may all contribute to the devel-
opment of hyponatremic states in recreational ecstasy
users. Even loss of sodium into the gastrointestinal tract
has been discussed (24).
The AVP system is activated by factors typically asso-
ciated with MDMA consumption in a party setting in-
A
E F G H
B C D
FIG. 2. Mean values  SEM for sodium and osmolality in urine and plasma in eight female and eight male healthy subjects 4 h before (PRE) and
120 min after MDMA (125 mg) or placebo. The two treatment conditions including MDMA (placebo-MDMA and duloxetine-MDMA) tended to
increase both urine osmolality (A and B) and urine sodium levels (C and D) in both sexes. There were no treatment effects on plasma osmolality or
plasma sodium levels (E–H).
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cluding dehydration (12–14), heat (25), and physical ac-
tivity (12, 26), all of which are potentially increasing the
risk of SIADH. Our results indicate that direct activation
of the AVP system by MDMA may play a crucial facili-
tating role in the development of ecstasy-associated
SIADH, in particular in women, because we controlled
carefully for confounding factors that may increase AVP.
Subjects werewell hydrated orally and iv and resting com-
fortably in hospital beds in a temperature-controlled re-
search environment. Of note, our subjects drank more
water after MDMA than after placebo administration
possibly due to a dry mouth and increased thirst after
MDMAadministration (18). Fluid consumptionwouldbe
expected to decrease copeptin secretion (13), counteract-
ing the effects of MDMA. However, copeptin levels were
actually increased during the MDMA condition, which
further supports the concept that MDMA activated the
AVP system via pharmacological stimulation, although
we cannot exclude an indirect effect via increased thirst
perception (14). Furthermore, urine osmolality and urine
sodium levels tended to be higher afterMDMA compared
with placebo administration despite the increase in oral
fluid intake. This finding indicates thatMDMA increased
renal fluid retention, which is consistent with an elevated
secretion of AVP.
The AVP response to MDMA in women was blocked
by duloxetine pretreatment. Duloxetine prevents the
transporter-mediated release of serotonin and norepi-
nephrine by MDMA. Thus, MDMA-induced AVP secre-
tion appears to bemediated by serotonin and norepineph-
rine. This clinical finding is in line with preclinical studies
indicating a role for central serotonin (8) and norepineph-
rine (9) systems in AVP secretion. The mediating role of
the serotonin system in AVP regulation is also supported
by the fact that several serotonergic medications are typ-
ically associatedwithan increased riskof SIADH(22).The
precise mechanism of the serotonin/norepinephrine-AVP
system interaction is not known. AVP and copeptin are
also hypothalamic stress hormones (27, 28), andMDMA
is a pharmacological stressor. MDMA activates the hy-
pothalamo-pituitary-adrenal axis and increases plasma
corticotropin and cortisol (29, 30). In addition, MDMA
increases aldosterone secretion in rats. Cortisol and min-
eralocorticoids also influence the electrolyte and body
fluid balance. We did not assess the role of steroids in the
present study. However, steroids increase renal sodium
reabsorption and would thereby antagonize AVP effects
on plasma osmolality.
In our study, MDMA (125 mg) had no effect on AVP
or copeptin plasma levels in male subjects, whereas an
earlier study showed an increase inAVP after a lower dose
of MDMA (47.5 mg) in eight healthy men (5, 6). This
discrepancy is likely due to differences in the study design
and setting. Importantly, subjects were free to drink as
much as they wanted in our study, and fluid consumption
was higher after MDMA than after placebo which could
have counteracted any MDMA effects on AVP secretion
and even abolished any MDMA effects in men. In addi-
tion, our subjectswere resting inhospital beds, eliminating
any contributing effects of physical activity on AVP se-
cretion. Nevertheless, it is surprising that our compara-
tively high dose ofMDMAdid not affect AVP or copeptin
secretion despite pronounced subjective and cardiovascu-
lar stimulant effects of MDMA in the same subjects (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data). Interestingly, similar inconsistencies are
seen in the clinical reports on ecstasy-associated hypona-
tremia. Hyponatremia was found in 55 (52.4%) of 105
women and 18 (21.7%) of 83 men in ecstasy exposures
reported to the California Poison Control System (3).
However, other reports indicate that hyponatremia is a
relatively rare complication of ecstasy use. Ecstasy-asso-
ciated hyponatremiawas observed in only two (5%) of 40
monointoxications (31) or was not reported (32) accord-
ing to other poison center studies. Hyponatremiawas also
a rare medical complication according to a series of in-
toxication cases presenting to emergency rooms (17, 33,
34). Taken together, the available data point toward an
important role of additional contributing personal (sex,
menstrual phase, and genetic factors) and/or environmen-
tal (heat and hydration) factors that may contribute and
modulate the effects of MDMA on AVP secretion and
osmotic regulation.
Our studyhas several limitations.The study sample size
is relatively small. Only single doses of MDMA and du-
loxetine were used. However, the doses were selected in
the upper dose range and produced pronounced effects on
a variety of outcomes. Importantly, the absolute dose of
MDMAwas the same in both sexes and was not adjusted
for body weight, resulting in higher relative doses of
MDMAper kilogramof bodyweight inwomen compared
with men. Thus, we cannot exclude that the observed sex
difference was in fact a dose effect with women receiving
higher relative doses of MDMA than men. However, rel-
ative MDMA doses did not correlate with MDMA-in-
duced changes in copeptin levels within the male and fe-
male groups, supporting the view that our finding
represents a true sex difference and not a dose effect. Fur-
thermore, fluid consumption was different across treat-
ment conditions, which may have counteracted effects of
MDMA on AVP secretion because subjects consumed
more liquids after MDMA than after placebo administra-
tion. Finally, urine osmolality and associated AVP system
activationwas higher inmen thanwomen at the beginning
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of the study, which may have differentially affected the
response to MDMA.
With regard to the validity of theoutcomemeasures,we
documented a correlation of plasma AVP and copeptin,
confirmingprevious studies (12, 14). In addition, copeptin
plasma concentrations also weakly correlated with
plasma and urine osmolalities as expected based on os-
moregulation and as previously documented in hypo-,
iso-, and hyperosmolar states in healthy subjects (14). We
also confirmed the previously reported sex differences in
basal plasma copeptin concentration (12, 13).
In conclusion, we found thatMDMA increased copep-
tin plasma levels reflecting AVP system stimulation in
women but not in men. The finding is consistent with an
increased risk for the development of hyponatremia and
associated complications after recreational ecstasy use in
women compared with men. AVP system activation by
MDMAis likelydue to the serotonin- andnorepinephrine-
releasing properties of MDMA.
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